Tian Lei, Zhou Huandi, Wang Guohui, Wang Wen Yan, Li Yuehong, Xue Xiaoying
Department of Radiotherapy, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Department of Pathology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
PeerJ. 2021 May 14;9:e11422. doi: 10.7717/peerj.11422. eCollection 2021.
Glioma is the most common type of intracranial tumor with high malignancy and poor prognosis despite the use of various aggressive treatments. Targeted therapy and immunotherapy are not effective and new biomarkers need to be explored. Some Procollagen-lysine 2-oxyglutarate 5-dioxygenase () family members have been found to be involved in the metastasis and progression of tumors. Both and had been reported to be highly expressed in gliomas, while the prognostic value of remains to be further illustrated, so we want to investigate the expression in glioma and its clinical implication.
We collected gene expression and corresponding clinical data of glioma from the Chinese Glioma Genome Atlas (CGGA) database, The Cancer Genome Atlas (TCGA) database and the Gene Expression Omnibus (GEO) database. First, we analyzed the expression and mutation of in gliomas and its relationship with clinicopathologic characteristics. Then, we conducted survival analysis, prognostic analysis and nomogram construction of the gene. Finally, we conducted gene ontology (GO) enrichment analysis and gene set enrichment analysis (GSEA) to explore possible mechanisms and gene co-expression analysis was also be performed.
The results showed that the expression level of was higher in gliomas than normal tissues, and high expression of was related to poor survival which can serve as an oncogenic factor and an independent prognostic indicator for glioma patients. Both the GO and GSEA analysis showed high expression of were enriched in Extracellular matrix (ECM) related pathways, the co-expression analysis revealed that was positively related to , , , , , , , , and , and high expression of these genes were also correlated to poor prognosis of glioma.
The results showed that high expression of leads to poor prognosis, and is an independent prognostic factor and a novel biomarker for the treatment of glioma. Furthermore, targeting is most likely a potential therapeutic strategy for glioma patients.
胶质瘤是最常见的颅内肿瘤类型，尽管采用了各种积极的治疗方法，但其恶性程度高且预后差。靶向治疗和免疫治疗效果不佳，需要探索新的生物标志物。已发现一些脯氨酸赖氨酸2-氧戊二酸5-双加氧酶（）家族成员参与肿瘤的转移和进展。据报道，和在胶质瘤中均高表达，而的预后价值仍有待进一步阐明，因此我们想研究在胶质瘤中的表达及其临床意义。
我们从中国胶质瘤基因组图谱（CGGA）数据库、癌症基因组图谱（TCGA）数据库和基因表达综合数据库（GEO）中收集了胶质瘤的基因表达及相应临床数据。首先，我们分析了在胶质瘤中的表达、突变情况及其与临床病理特征的关系。然后，我们对基因进行了生存分析、预后分析并构建了列线图。最后，我们进行了基因本体（GO）富集分析和基因集富集分析（GSEA）以探索可能的机制，并且还进行了基因共表达分析。
结果显示，在胶质瘤中的表达水平高于正常组织，的高表达与较差的生存率相关，可作为胶质瘤患者的致癌因素和独立预后指标。GO分析和GSEA分析均显示，的高表达富集于细胞外基质（ECM）相关通路，共表达分析显示与、、、、、、、、呈正相关，这些基因的高表达也与胶质瘤的不良预后相关。
结果表明，的高表达导致预后不良，是一个独立的预后因素，也是治疗胶质瘤的新型生物标志物。此外，靶向治疗很可能是胶质瘤患者的一种潜在治疗策略。
